STOCK TITAN

Alkermes to Take Part in the Goldman Sachs Annual Global Healthcare Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

DUBLIN, June 3, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) announced today that management will participate in a virtual fireside chat at the Goldman Sachs 42nd Annual Global Healthcare Conference on Wednesday, June 9, 2021 at 10:30 a.m. ET (3:30 p.m. BST). The presentation may be accessed under the Investors tab on www.alkermes.com and will be archived for 14 days.

About Alkermes plc

Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes plc has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com

Contact:
Alex Braun
Investor Relations
+1 781 296 8493

Alkermes plc Logo (PRNewsfoto/Alkermes plc)

Cision View original content to download multimedia:http://www.prnewswire.com/news-releases/alkermes-to-take-part-in-the-goldman-sachs-annual-global-healthcare-conference-301305712.html

SOURCE Alkermes plc

Alkermes plc

NASDAQ:ALKS

ALKS Rankings

ALKS Latest News

ALKS Stock Data

Pharmaceutical Preparation Manufacturing
Manufacturing
Link
Health Technology, Biotechnology, Manufacturing, Pharmaceutical Preparation Manufacturing

About ALKS

alkermes plc is a fully integrated, global biopharmaceutical company developing innovative medicines for the treatment of central nervous system (cns) diseases. the company has a diversified commercial product portfolio and a substantial clinical pipeline of product candidates for chronic diseases that include schizophrenia, depression, addiction and multiple sclerosis. headquartered in dublin, ireland, alkermes plc has an r&d center in waltham, massachusetts; a research and manufacturing facility in athlone, ireland; and a manufacturing facility in wilmington, ohio. for more information, please visit alkermes’ website at www.alkermes.com.